

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
29 April 2004 (29.04.2004)

PCT

(10) International Publication Number  
WO 2004/035031 A3

(51) International Patent Classification<sup>7</sup>: A61K 31/506

(21) International Application Number:  
PCT/EP2003/011601

(22) International Filing Date: 20 October 2003 (20.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0224455.6 21 October 2002 (21.10.2002) GB

(71) Applicants and

(72) Inventors: ALL-ERICSON, Charlotta [SE/SE]; Brynhildsvägen 15, S-167 73 Bromma (SE). LARSSON, Olle [SE/SE]; Svargränd 9, S-187 42 Täby (SE). SEREGARD, Stefan [SE/SE]; Oxenstiernsgatan 25, S-115 27 Stockholm (SE).

(74) Agent: GRUBB, Philip; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).


Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:  
15 July 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TREATMENT OF UVEAL MELANOMA



(I)

(57) Abstract: The present invention pertains to the use of the Compound (I) of the following formula or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of uveal melanoma.

WO 2004/035031 A3